Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Cash from Operations (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Cash from Operations for 2 consecutive years, with 1998000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 85.89% to 1998000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 4992000.0 through Dec 2025, up 72.84% year-over-year, with the annual reading at 4992000.0 for FY2025, 72.84% up from the prior year.
  • Cash from Operations hit 1998000.0 in Q4 2025 for Xilio Therapeutics, up from 17495000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 28978000.0 in Q1 2025 to a low of 17495000.0 in Q3 2025.